Aberrant expression of CD1 molecules in mDCs in CVID is normalized by IVIg. (A) Representative staining-and-gating strategy. (B) Comparison of the level of CD1c+ mDCs between healthy control participants and patients with CVID, and in these patients before and after IVIg treatment. Comparison of the levels of CD1a expression (C); CD1b expression (D); CD1d expression (E); and CD1a, CD1b, and CD1d triple-expression (F) on CD1c+ mDCs between healthy control participants and patients with CVID, and in these patients before and after IVIg treatment. **P < .01 and *P < .05.